Janjira Petsuksiri

Dr. Janjira Petsuksiri


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2022 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
PDPittaya Dankulchai
Pittaya Dankulchai
PHPetcharat Harn-Utairasmee
Petcharat Harn-Utairasmee
TPTissana Prasartseree
Tissana Prasartseree
PNPitchayut Nakkasae
Pitchayut Nakkasae
KTKyrhatii Trikhirhisthit
Kyrhatii Trikhirhisthit
YCYaowalak Chansilpa
Yaowalak Chansilpa

20 January 2023 in Current Oncology
Verified
Journal Article
Open access
PDF file
KAKawita Atipas
Kawita Atipas
NLNatthawadee Laokulrath
Natthawadee Laokulrath
JPJanjira Petsuksiri
Janjira Petsuksiri
NRNarin Ratanaprasert
Narin Ratanaprasert
WPWarut Pongsapich
Warut Pongsapich
Human papillomavirus (HPV) infection detected in oropharyngeal squamous cell carcinoma (OPSCC) is associated with a better survival outcome from previous literature. However, Thailand and several Asian countries have a low prevalence of HPV-associated OPSCC and, therefore, have a low positive rate of immunostaining with p16. Tumor microenvironments (TME), including tumor-infiltrating CD8+ lymphocytes (CD8+ TIL) and programmed death ligand 1 (PD-L1), are proposed as significant prognostic indicators in addition to p16. Objectives: Explore the expression p16, CD8+ TIL, and PD-L1 and its value as prognostic indicators for overall survival (OS) in patients with OPSCC. Materials and Methods: Data from patients with OPSCC diagnosed from 2012 to 2018 were recovered from medical records and national registry. All available glass slides and slides of immunohistochemistry (IHC) of p16, CD8, and PD-L1 were reviewed. The TME was classified into four types according to the expression pattern of PD-L1 and CD8+TIL. Overall survival (OS) was assessed using the Kaplan–Meier method and Cox regression model analysis. Results: In 160 OPSCC patients, p16 was positive in 27 (16.88%). The density of CD8+ TIL was higher in the p16+ and PD-L1+ groups (p = 0.005, 0.039); however, there was no association between p16 and the status of PD-L1. P16 and CD8+ TIL were significant prognostic factors for better OS (p = 0.007, 0.001), but not PD-L1 status (p = 0.317). Among the four types of TME, carcinoma showed mainly type IV TME (PD-L1−/TIL+), while OPSCCs with type I TME (PD-L1+/TIL+) had the best survival outcome. Conclusions: The positivity of p16 and the density of CD8+ TIL were associated with better OS in OPSCC, while the status of PD-L1 was not significantly related to OS. OPSCC with type I TME (PD-L1+/TIL+) showed the best prognosis of all types of TME.

1 January 2016 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
STSuwanit Therasakvichya
Suwanit Therasakvichya
SKSompop Kuljarusnont
Sompop Kuljarusnont
JPJanjira Petsuksiri
Janjira Petsuksiri
PCPattama Chaopotong
Pattama Chaopotong
VAVuthinun Achariyapota
Vuthinun Achariyapota
AJAtthapon Jaishuen
Atthapon Jaishuen
Therasakvichya S, et al. J Gynecol Oncol. 2016 May;27(5):e48. https://doi.org/10.3802/jgo.2016.27.e48

1 March 2014 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
JSJiraporn Setakornnukul
Jiraporn Setakornnukul
JPJanjira Petsuksiri
Janjira Petsuksiri
SWSirentra Wanglikitkoon
Sirentra Wanglikitkoon
MWMalee Warnnissorn
Malee Warnnissorn
KTKullathorn Thephamongkhol
Kullathorn Thephamongkhol
VVVutisiri Veerasarn
Vutisiri Veerasarn
Long Term Outcomes of Patients with Endometrial Carcinoma Treated with Radiation - Siriraj Hospital Experience Endometrial carcinoma;radiation therapy;survival;central pathological review;FIGO 2009; Background: To evaluate treatment outcomes of patients with stage I-III endometrial cancer treated with postoperative radiation. Materials and Methods: A retrospective review of 166 endometrial cancer patients, undergoing surgery and postoperative radiotherapy at Siriraj Hospital from 2005-2008 was performed. Pathology was reviewed. Results of treatment were reported with 5-year loco-regional recurrence free survival (LRRFS), 5-year overall survival (OS), patterns of failure and toxicity, and according to stage and risk groups. Results: Median follow up time was 62.8 months. Pathological changes were found in 36.3% of the patients after central reviews, leading to 19% changes in risk groups. Most of the patients (83.7%) received pelvic radiation (PRT) and vaginal brachytherapy (VBT). Five-year LRRFS and OS of all patients were 94.9% and 85.5%, respectively. There was no recurrence or death in low and low-intermediate risk groups. For the high-intermediate risk group, 5-year LRRFS and OS were 96.2% and 90.8%, respectively, and for the high risk group 90.5% and 71%. Late grade 3 and 5 gastrointestinal toxicity was found in 3% and 1.2% of patients, respectively. All of them received PRT 5,000 cGy in 25 fractions. Conclusions: Low and intermediate risk patients had good results with surgery and adjuvant radiation therapy. For high risk patients, postoperative radiation therapy alone appeared to be inadequate as the most common pattern of failure was distant metastasis.

3 October 2023 in Journal of Obstetrics and Gynaecology Research
Verified
Journal Article
Closed access
JPJanjira Petsuksiri
Janjira Petsuksiri
JSJiraporn Setakornnukul
Jiraporn Setakornnukul
ABAniwat Berpan
Aniwat Berpan
KTKullathorn Thephamongkhol
Kullathorn Thephamongkhol
PDPittaya Dankulchai
Pittaya Dankulchai
AJAtthapon Jaishuen
Atthapon Jaishuen

1 February 2024 in JCO Global Oncology
Verified
Journal Article
Open access
JSJiraporn Setakornnukul
Jiraporn Setakornnukul
JPJanjira Petsuksiri
Janjira Petsuksiri
PCPanid Chaysiri
Panid Chaysiri
PDPongwut Danchaivijitr
Pongwut Danchaivijitr
NNNuttapong Ngamphaiboon
Nuttapong Ngamphaiboon
KTKullathorn Thephamongkhol
Kullathorn Thephamongkhol
PURPOSE: Concurrent chemoradiotherapy followed by adjuvant chemotherapy (CRT-AC) and induction chemotherapy followed by concurrent chemoradiotherapy (IC-CRT) are among the best treatments in nasopharyngeal carcinoma (NPC). This study aimed to develop a model for deciding the sequence of chemotherapy in NPC. METHODS: Data were separated into two cohorts. The CRT-AC cohort had 295 patients, while the IC-CRT cohort had 112. The predictors were standard factors with BMI and neutrophil-lymphocyte ratio (NLR) to predict overall survival (OS). A flexible parametric survival model was used. RESULTS: A total of 132 (44.7%) and 72 patients (64.3%) died in the CRT-AC and IC-CRT cohorts, respectively. The predictors in the final models were age, sex, T, N, NLR, and BMI. The models of OS for CRT-AC and IC-CRT had concordance indices of 0.689 and 0.712, respectively, with good calibration curves. When changing the burden of disease along with NLR and BMI, we found that CRT-AC was not significantly different OS from IC-CRT when low NLR (<3) and high burden of disease (T3N3). By contrast, CRT-AC was remarkably more effective when there were high levels of NLR (≥3) and BMI (≥25) with any burden of disease (anyT anyN). CONCLUSION: With additional BMI and NLR in model, it could be easier to decide between CRT-AC and IC-CRT in countries with limited health care resources.